Drug ID:Drug161
Drug Name:BMS-986166
CID:118877516
DrugBank ID:DB19053
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03038711
Molecular Formula:C25H33NO2
Molecular Weight:379.5 g/mol
Isomeric SMILES:COC1=CC=CC=C1CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]4CC[C@@](C4)(CO)N
Synonyms:Udifitimod; BMS-986166; Udifitimod [USAN]; UNII-283FTA936D; 283FTA936D; [(1R,3S)-1-amino-3-[(6S)-6-[2-(2-methoxyphenyl)ethyl]-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol; Udifitimod (USAN); BMS986166; ((1R,3S)-1-amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; compound 14a [PMID: 30785748]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1223 118877516 Bms-986166 1901 S1PR1 Homo sapiens (human) 30785748 Partial agonist

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03038711 A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers PHASE1 COMPLETED Bristol-Myers Squibb Ulcerative Colitis DRUG: BMS-986166|OTHER: Placebo matching BMS-9861… Details
NCT00787202 A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… Details
NCT03773952 Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients PHASE2 COMPLETED Palobiofarma SL Ulcerative Colitis DRUG: PBF-677|DRUG: Placebo oral capsule Details
NCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio PHASE3 RECRUITING Alvotech Swiss AG Ulcerative Colitis BIOLOGICAL: AVT16|BIOLOGICAL: Vedolizumab Details
NCT06109441 Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics PHASE2 RECRUITING AltruBio Inc. Ulcerative Colitis BIOLOGICAL: ALTB-268 Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05177835 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464 Details
NCT05807971 Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects PHASE1 COMPLETED Athos Therapeutics Inc Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… DRUG: ATH-063|DRUG: Placebo Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT02840721 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. PHASE2 COMPLETED Telavant, Inc. Colitis, Ulcerative DRUG: PF-06480605 Details
NCT04133194 Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis PHASE4 RECRUITING Flemming Bendtsen Ulcerative Colitis DRUG: Mesalazine|DRUG: Mesalazine Details
NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis PHASE2|PHASE3 RECRUITING Bristol-Myers Squibb Colitis, Ulcerative DRUG: Ozanimod Details
NCT01465763 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT01100112 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets PHASE3 COMPLETED Bausch Health Americas, Inc. Colitis, Ulcerative DRUG: Budesonide Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT03093259 ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo oral capsule Details
NCT01458951 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT00628433 Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis PHASE1|PHASE2 COMPLETED Harbor Therapeutics Ulcerative Colitis DRUG: Placebo|DRUG: HE3286 Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S02 Immunosuppression Classic immunosuppressive drugs azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus Ciclosporin-A and tacrolimus bind to specific intracellular… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations